- Home
- CCM vs MTVA Comparison
CCM vs MTVA Comparison
Compare CCM & MTVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCM
- MTVA
- Stock Information
- Founded
- CCM 1997
- MTVA 2014
- Country
- CCM China
- MTVA United States
- Employees
- CCM N/A
- MTVA N/A
- Industry
- CCM Medical/Nursing Services
- MTVA
- Sector
- CCM Health Care
- MTVA
- Exchange
- CCM Nasdaq
- MTVA NYSE
- Market Cap
- CCM 18.2M
- MTVA 15.1M
- IPO Year
- CCM 2009
- MTVA N/A
- Fundamental
- Price
- CCM $7.05
- MTVA $0.69
- Analyst Decision
- CCM
- MTVA Strong Buy
- Analyst Count
- CCM 0
- MTVA 2
- Target Price
- CCM N/A
- MTVA $7.50
- AVG Volume (30 Days)
- CCM 26.2K
- MTVA 598.1K
- Earning Date
- CCM 06-17-2025
- MTVA 05-14-2025
- Dividend Yield
- CCM N/A
- MTVA N/A
- EPS Growth
- CCM N/A
- MTVA N/A
- EPS
- CCM N/A
- MTVA N/A
- Revenue
- CCM $52,603,198.00
- MTVA N/A
- Revenue This Year
- CCM N/A
- MTVA N/A
- Revenue Next Year
- CCM N/A
- MTVA N/A
- P/E Ratio
- CCM N/A
- MTVA N/A
- Revenue Growth
- CCM N/A
- MTVA N/A
- 52 Week Low
- CCM $3.80
- MTVA $0.63
- 52 Week High
- CCM $26.70
- MTVA $5.30
- Technical
- Relative Strength Index (RSI)
- CCM 49.10
- MTVA N/A
- Support Level
- CCM $6.70
- MTVA N/A
- Resistance Level
- CCM $7.67
- MTVA N/A
- Average True Range (ATR)
- CCM 0.58
- MTVA 0.00
- MACD
- CCM -0.19
- MTVA 0.00
- Stochastic Oscillator
- CCM 12.59
- MTVA 0.00
About CCM Concord Medical Services Holdings Limited
Concord Medical Services Holdings Ltd operates radiotherapy and diagnostic imaging centers in China. The company operates cooperative centers across several provinces and administrative regions in China. Its network includes radiotherapy centers, diagnostic imaging centers, and centers providing other treatment and diagnostic services, such as electroencephalography for the diagnosis of epilepsy, thermotherapy to increase the efficacy of and for pain relief after radiotherapy and chemotherapy, high-intensity focused ultrasound therapy for the treatment of cancer, stereotactic radiofrequency ablation for the treatment of Parkinson's Disease and refraction and tonometry for the diagnosis of ophthalmic conditions.
About MTVA METAVIA INC
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is designed to be administered once weekly subcutaneously.